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The hemophilias are the most common X-linked inherited bleeding disorders. The challenges in children are
different from that in adults and, If not properly managed, can lead to chronic disease and lifelong disabilities.
Currently, inhibitors are the most severe complication and prophylaxis is emerging as the optimal preventive care
strategy. Quality of life has become in the western countries the primary objective of the process of providing care,
thus all the strategies (psychotherapy, physiotherapy, community life), not just the infusion of the missing factor,
should be activated for the patient and family to give them the perception of being healthy.In the past three decades, haemophilia has moved from the
status of a neglected and often fatal hereditary hemorrhagic
disorder to that of a defined group of well-characterized
molecular entities. This publication collecting the, consid-
ered by experts, most valuable bibliography is intended
to be an introduction to newly care of the hemophilic
children, as a small handbook for the clinical practice of
pediatrician. There is little doubt at the moment that,
among the most prevalent monogenic disorders (cystic
fibrosis, thalassemia, muscular dystrophy), haemophilia
enjoys the most efficacious and safe treatment. Indeed,
after the dramatic events of widespread blood-borne
virus transmission in the 1970s–1980s, there has been a
strong drive towards a continuous improvement in the
efficacy and safety of replacement therapy [1] and
towards the cure of the disease through gene therapy
[2]. Although the safety of plasma-derived factors has
dramatically improved in the last 25 years, the fear
related to the possible transmission by blood or its
derivates of new or unknown pathogens has prompted
the haemophilia treaters of western countries to treat
previously untreated hemophilic babies mainly with
recombinant products [3]. In parallel, with safety as a
priority in mind, also the manufacturing process of
recombinant factors evolved during the last few years to
further minimize the risk of pathogen transmission,
through the improvement of protein purification tech-
niques, the addition of viral inactivation steps and the* Correspondence: paola.giordano@uniba.it
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reproduction in any medium, provided the oravoidance of human or animal proteins at any stage of
their manufacturing process [4,5]. The availability for
replacement therapy of safe high-quality factor concen-
trates was important not only for reducing the likeli-
hood of death from haemorrhage but also for the broad
implementation of prophylactic treatment regimens in
order to prevent joint bleeding and resultant arthro-
pathy, ultimately allowing patients to maintain a near
normal lifestyle [6]. Quality of life has become in the
western countries the primary objective of the process
of providing care, which evolved from the infusion of
the missing factor, the activation of all the strategies
(psychotherapy, physiotherapy, community life) aimed
to make the patient and family to perceive themselves
as health. Prophylaxis is the gold standard for preserv-
ing joint function in babies with severe haemophilia.
Primary prophylaxis is defined as regular treatment,
given for at least 45 weeks of the year, initiated in the
absence of documented osteochondral joint disease,
determined by physical examination and/or imaging
studies, and started before the second clinically evident
large joint bleed and age 3 years. Secondary prophylaxis
is defined as regular treatment started after two or more
bleeds into ankles, knees, hips, elbows or shoulders and
before the onset of joint disease documented by physical
examination and imaging studies, given for at least
45 weeks of the year. Finally, tertiary prophylaxis is
described as regular continuous treatment started after
the onset of joint disease documented by physical exam-
ination and plain radiographs of the affected joints. The
goal of prophylaxis is to maintain a FVIII concentration
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ministration of FVIII 10–15 U/kg/daily or 20–40 IU/kg
every second day or at least three times weekly for patients
with haemophilia A and every third day or twice weekly
for patients with haemophilia B. “Inter-mediate-dose
protocols” are exemplified by protocols developed in
The Netherlands, use lower doses administered slightly
less frequently (e.g., 15–25 IU/kg, 2–3 times/week).
Furthermore in these regimens doses are often adjusted
according to clinical needs. However, many different
protocols are followed for prophylaxis, even within the
same country, and the optimal regimen remains to be
defined [7]. PEDNET, the European Paediatric Network
for Haemophilia Management based on the collabor-
ation of 23 paediatricians from 16 European countries,
have thus recently provided the following new defini-
tions, precisely describing the differences between treat-
ment schedules:
 Primary prophylaxis A is the regular continuous
treatment started after the first joint bleed and
before the age of 2 years while
 Primary prophylaxis B refers to regular continuous
treatment started before the age of 2 years without
previous joint bleeds [8].
One option for the treatment of very young children is
to start prophylaxis once a week and escalate depending
on bleeding and venous access. Prophylaxis is best given
in the morning to cover periods of activity. Prophylactic
administration of clotting factor concentrates is advisable
prior to engaging in activities with higher risk of injury [7].
In the current favourable context, the most challenging
complication of therapy has become the development of
inhibitory alloantibodies against FVIII or FIX. These
inhibitors, that develop in 25-30% of severe hemophilia
A patients and in only 3-5% of those with hemophilia B,
render replacement therapies ineffective [9,10]. Several
issues have been reported regarding inhibitors develop-
ment in children with hemophilia: host predisposition
to FVIII inhibitors has been underscored by the import-
ance of hemophilic mutation, family history, and race in
predicting risk. Consequently, hemophilia genotype and
immunogenetic influences have been well studied
through large national and international cohorts. While
null mutations in the F8 gene predispose severe
hemophilia A patients to a 21-88% risk of antibody de-
velopment, underlying risk diminishes to <10% in those
with genotypes resulting in production of truncated
nonfunctional FVIII. The inconsistency of this associ-
ation when applied to the inversion mutations may now
be explained by the recently implicated role of residual
intracellular FVIII in modifying immunogenicity [11].
Among the many implicated treatment-related riskfactors for inhibitor development in severe hemophilia
A, FVIII product type, treatment intensity and FVIII
prophylaxis have been the most controversial and/or
the most thoroughly investigated. The retrospective
CANAL study did not demonstrate an inhibitor-
protective effect of pdFVIII in the treatment of children
with severe hemophilia A [12]. Confirmatory data from
the prospective RODIN cohort are now available [13].
Furthermore, a metaanalysis of published studies by
Franchini et al. also determined that the overall preva-
lence of all and high titer inhibitors was not statistically
different between rFVIII and pdFVIII treated [14]. The
ongoing international SIPPET study is using a prospect-
ive randomized trial design to study the impact of FVIII
product type on inhibitor development in minimally
treated children with severe hemophilia A [15]. In a
large retrospective study, intense FVIII replacement
therapy administered to pediatric patients with severe
hemophilia A during the first 50 FVIII exposure days
was associated with an increased risk of inhibitor devel-
opment, particularly when defined by five consecutive
days of treatment (adjusted RR: 1.6). Furthermore, when
the need for surgical prophylaxis, rather than a singular
bleeding event or other indication for prophylaxis pro-
voked the first treatment episode, the adjusted relative risk
of inhibitor development was 2.6 [10]. This observation
was corroborated by Maclean and associates. In an ana-
lyses of severe hemophilia A children in the UKHCDO
database, 5 days of consecutive treatment was associated
with adjusted odds ratios of 2.51 (P < 0.014) for all
inhibitor development and 3.11 (P < 0.007) when high
titer inhibitors are specifically considered [16]; lastly, in
corroboration of earlier observations suggesting a pro-
tective effect of prophylaxis in smaller national cohorts
[17,18], the retrospective CANAL study data further
suggested an adjusted RR of 0.5 for inhibitor develop-
ment in prophylaxis patients when compared to severe
hemophilia A patients treated with on demand FVIII
replacement [10]. Study data suggest that early prophy-
lactic treatment and avoidance of intensive treatment
periods may also protect patients from the risk of in-
hibitor development [19]. In Bremen and other German
haemophilia centres, the implementation of a protocol
of early prophylaxis, started with once weekly injections
before the first joint bleed, has resulted in a very low
rate of inhibitor formation [20]. Inhibitors should be
screened once every 5 exposure days until 20 exposure
days, every 10 exposure days between 21 and 50 exposure
days, and at least two times a year until 150 exposure days.
Inhibitor measurement should also be done in all patients
who have been intensively treated for more than 5 days,
within 4 weeks of the last infusion. Moreover, inhibitors
should also be assessed prior to surgery or if recovery
assays are not as expected, and when clinical response to
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period [21]. The introduction of bypassing agents, such as
activated prothrombin complex concentrates (APCC)
(Factor Eight Inhibitor Bypassing Activity-FEIBA) and
recombinant activated factor VII (rFVII, NovoSeven), has
improved the management of children with inhibitors
[16]. With the widespread adoption of primary prophy-
laxis programs and the implementation of antigen-specific
immune tolerance induction (ITI) regimens requiring
regular infusion of high doses of factor concentrates,
the route of administration of replacement therapy
has become a crucial issue [22]. Although peripheral
venipuncture is the first choice, central venous access
devices (CVADs) are often necessary in very young
children with poor venous access. Totally implantable
catheters (ports) should be preferred over external
CVADs due to the lower rate of complications, espe-
cially infections and thrombosis [23]. Recently, arterio-
venous fistula has been demonstrated as a reliable way
to manage the venous access in haemophilic children
[24]. The most likely progress in this field is the avail-
ability of FVIII and FIX molecules with longer half lives.
This would be a significant step forward, considering
that in countries that can afford primary prophylaxis
the main obstacles to its widespread adoption are
problems related to venous access. Several companies
are currently developing factors with longer half-life to
obviate frequent administration, and/or reduced antige-
nicity/immunogenicity to minimize inhibitor develop-
ment [25]. The main strategies being applied to FVIII
include modifications of the molecule, such as the addition
of polyethylene glycol (PEG) polymers or polysialic acids,
and alternative formulation with PEG-modified liposomes
(PEGLip) [26]. Improved pharmacokinetics properties
of coagulation factors have also been obtained through
molecule modification by genetic fusion with albumin
and the IgG Fc moiety [27,28]. In the last decade the
ultimate goal of the investigators has been the search of
the definitive cure through gene transfer of the under-
lying DNA defect [11,29]. The most promising clinical
results in haemophilia currently are for haemophilia B,
where intravenous infusion of an adeno-associated viral
(AAV) vector encoding factor IX (FIX) under the control
of a liver-restricted promoter has resulted in expression of
FIX at plateau levels ranging from 1% to 6%, for periods of
2 years, in 6 adult males with severe haemophilia B [30].
Four of these 6 subjects, who were enrolled in the United
Kingdom where twice-weekly prophylactic infusion of FIX
concentrates is standard of care, have now been able to
discontinue routine prophylaxis, reserving factor infusion
for surgery or trauma, and the other 2 have been able to
reduce the frequency of factor infusions. Those who
stopped prophylaxis have largely been free of spontaneous
bleeding episodes, confirming what had been predictedbased on results in haemophilic dogs treated with the
same approach [31] and on the natural history of mildly
affected haemophilia patients. The safety of the approach
to date has been excellent, with the only adverse event
related to the study agent being a rise in liver enzymes
(aspartate aminotransferase and alanine aminotransferase),
accompanied by a decline in FIX levels, which resolved
after a course of tapering steroids. Recently, interesting
results of a same approach in Haemophilia A have been
reported in three nonhuman primates (macaques) that
showed human FVIII expression above 100% but devel-
oped neutralizing anti-FVIII antibodies that were abro-
gated with transient immunosuppression [32]. However
AAV-mediated gene transfer to liver may have limited suc-
cess in young children, as AAV vectors are predominantly
non-integrating and expression is gradually lost if vector is
injected into a growing animal [11]. To maintain this high
level of health care and research two elements are essen-
tial. First, there is a need of more international collabora-
tions in clinical research on haemophilia. Indeed, very few
of the aforementioned cogent unsolved questions can be
tackled by studies done in single, albeit large, haemophilia
centers. The adequacy of the sample size is essential also
for a rare disease such haemophilia and this goal can be
achieved only through collaborative multicenter studies.
Secondly, it is necessary to maintain a high interest and
expertise in the field of haemophilia, especially among
newer generations of physicians [33]. With this overall
philosophy the AIEOP (Italian Paediatric Haematology
Oncology Association) is promoting the care for the
hemophiliac child in the associated centers. The manage-
ment of hemophilia patients is a model of comprehensive
care [34]. On this wave, we must be able to offer and guar-
antee (preferably in the same structure) services for the
prevention, diagnosis, treatment and rehabilitation appro-
priate to the magical world of children. The hemophiliac
child of the new millennium is, in western countries, a
child that can have treatment options that provide to live
a childhood almost similar to that of their peers, and
therefore must socialize and live in community. He’s a
child that can and should safety engage in physical activity.
He’s a child that with his family is to be supported by a
team of psychologists (developmental) experts of chronic
diseases. The role of the pediatrician is crucial because it
must, clutching a bond of trust with the child, be able to
coordinate all care-givers to accompany his growth step
by step. With the availability of prenatal diagnosis of
hemophilia, the counselor must be able to provide appro-
priate information to the couple, and staff maternity care
providers (obstetrician, neonatologist, nurses …) should be
able to handle the delivery and the possible first manifesta-
tions of haemophilia. The infant is not a small man, but a
puppy in evolution. A puppy who sees, in each of its
psychomotor acquisition stages, change his biochemical
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characteristics of his relationship with the world around
him. The child with hemophilia must be adequately
informed of his condition so that he can manage his path
toward the adult age through school and work. Physical
activity is healthy and needed for both the body and the
mind. Walking, swimming, running helps to strengthen
muscles and stabilize joints. Until recently, contact and
high impact sports such as rugby, boxing, judo, karate has
been banned to hemophilic children for the high risk of
injuries that can cause bleeding; It has been reported few
years ago that prophylaxis can effectively protect haemo-
philic children in sports that was not advised to them in
the past years [35]. There is still much to investigate: gene
therapy, drugs with a longer half-life (or to be given
orally), immunology of inhibitors, biochemical basis of
osteogenesis and joint damage [36,37]. The development
of specific instruments to access the quality of life of
hemophilic children [38] will allow us to better depict
these points with patients’ well being in mind.
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